期刊文献+
共找到46篇文章
< 1 2 3 >
每页显示 20 50 100
Use of Chinese Herbal Medicine Therapies in Comprehensive Hospitals in Central China: A Parallel Survey in Cancer Patients and Clinicians 被引量:3
1
作者 陈刚 乔婷婷 +5 位作者 丁浩 李晨曦 郑慧玲 陈晓玲 胡少明 于世英 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2015年第6期808-814,共7页
Summary: Chinese herbal medicine (CHM), as the largest application category of traditional Chinese medicine (TCM), is widely accepted among cancer patients in China. Herbal slice (HS) and Chinese patent drug (... Summary: Chinese herbal medicine (CHM), as the largest application category of traditional Chinese medicine (TCM), is widely accepted among cancer patients in China. Herbal slice (HS) and Chinese patent drug (CPD) are commonly used CHM in China. This study aimed to investigate the utilization of CHM among clinicians and cancer patients in central China. Five hundred and twenty-five patients and 165 clinicians in 35 comprehensive hospitals in central China were asked to complete an anonymous questionnaire that was designed to evaluate the use of CHM. The results showed that 90.74% clinicians and 72.24% cancer patients used CHM during cancer treatment. The educational backgrounds of the clinicians and the age, education level, annual income, and cancer stage of the cancer patients were re- lated to use of CHM. More than 90% clinicians and cancer patients had used CPD. Comparatively, the percentage of HS use was 10% lower than that of CPD use among clinicians and cancer patients. More clinicians preferred to use CHM after surgery than cancer patients did (20.41% vs. 5.37%). Enhancing physical fitness and improving performance status were regarded as the most potential effect of CHM on cancer treatment (85.71% among clinicians and 94.07% among cancer patients), in comparison with directly killing tumor cells (24.49% among clinicians and 31.36% among patients). As for refusal rea- sons, imprecise efficacy was the unanimous (100%) reason for clinicians' rejection of CHM, and 95.58% patients objected to using CHM also for this reason. Furthermore, the side effects of CHM were more concerned by clinicians than by patients (33.33% vs. 15.81%). In conclusion, our survey revealed that CHM was popularly accepted by clinicians and cancer patients in central China. The reasons of use and rejection of CHM were different between clinicians and cancer patients. 展开更多
关键词 A Parallel Survey in Cancer Patients and Clinicians use of Chinese Herbal Medicine Therapies in Comprehensive Hospitals in Central China
下载PDF
Impact of cardiologist intervention on guideline-directed use of statin therapy
2
作者 Manouchkathe Cassagnol Ofek Hai +4 位作者 Shaqeel A Sherali Kyla D’Angelo David Bass Roman Zeltser Amgad N Makaryus 《World Journal of Cardiology》 CAS 2020年第8期419-426,共8页
BACKGROUND Statins have an important and well-established role in the prevention of atherosclerotic cardiovascular disease(ASCVD).However,several studies have reported widespread underuse of statins in various practic... BACKGROUND Statins have an important and well-established role in the prevention of atherosclerotic cardiovascular disease(ASCVD).However,several studies have reported widespread underuse of statins in various practice settings and populations.Review of relevant literature reveals opportunities for improvement in the implementation of guideline-directed statin therapy(GDST).AIM To examine the impact of cardiologist intervention on the use of GDST in the ambulatory setting.METHODS Patients with at least one encounter at the adult Internal Medicine Clinic(IMC)and/or Cardiology Clinic(CC),who had an available serum cholesterol test performed,were evaluated.The 2 comparison groups were defined as:(1)Patients only seen by IMC;and(2)Patients seen by both IMC and CC.Patients were excluded if variables needed for calculation of ASCVD risk scores were lacking,and if demographic information lacked guideline-directed treatment recommendations.Data were analyzed using student t-tests or χ^2,as appropriate.Analysis of Variance was used to compare rates of adherence to GDST.RESULTS A total of 268 patients met the inclusion criteria for this study;211 in the IMC group and 57 in the IMC-CC group.Overall,56%of patients were female,mean age 56 years(±10.65,SD),22%Black or African American,56%Hispanic/Latino,14%had clinical ASCVD,13%current smokers,66%diabetic and 63%hypertensive.Statin use was observed in 55%(n=147/268)of the entire patient cohort.In the IMC-CC group,73.6%(n=42/57)of patients were prescribed statin therapy compared to 50.7%(n=107/211)of patients in the IMC group(P=0.002).In terms of appropriate statin use based on guidelines,there was no statistical difference between groups[IMC-CC group 61.4%(n=35/57)vs IMC group,55.5%(n=117/211),P=0.421].Patients in the IMC-CC group were older,had more cardiac risk factors and had higher proportions of non-white patients compared to the IMC group(P<0.02,all).CONCLUSION Although overall use of GDST was suboptimal,there was no statistical difference in appropriate statin use based on guidelines between groups managed by general internists alone or co-managed with a cardiologist.These findings highlight the need to design and implement strategies to improve adherence rates to GDST across all specialties. 展开更多
关键词 Statin use Guideline directed statin therapy CARDIOLOGIST Ambulatory care ADHERENCE
下载PDF
Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas
3
作者 Takuya Watanabe 《World Journal of Gastroenterology》 SCIE CAS 2023年第48期6179-6197,共19页
Follicular lymphoma(FL)is the most common indolent B-cell lymphoma(BCL)globally.Recently,its incidence has increased in Europe,the United States,and Asia,with the number of gastrointestinal FL cases expected to increa... Follicular lymphoma(FL)is the most common indolent B-cell lymphoma(BCL)globally.Recently,its incidence has increased in Europe,the United States,and Asia,with the number of gastrointestinal FL cases expected to increase.Genetic abnormalities related to t(14;18)translocation,BCL2 overexpression,NF-κB pathway-related factors,histone acetylases,and histone methyltransferases cause FL and enhance its proliferation.Meanwhile,microRNAs are commonly used in diagnosing FL and predicting patient prognosis.Many clinical trials on novel therapeutics targeting these genetic abnormalities and immunomodulatory mechanisms have been conducted,resulting in a marked improvement in therapeutic outcomes for FL.Although developing these innovative therapeutic agents targeting specific genetic mutations and immune pathways has provided hope for curative options,FL treatment has become more complex,requiring combinatorial therapeutic regimens.However,optimal treatment combinations have not yet been achieved,highlighting the importance of a complete understanding regarding the pathogenesis of gastrointestinal FL.Accordingly,this article reviews key research on the molecular pathogenesis of nodal FL and novel therapies targeting the causative genetic mutations.Moreover,the results of clinical trials are summarized,with a particular focus on treating nodal and gastrointestinal FLs. 展开更多
关键词 Gastrointestinal follicular lymphoma Genetic mutation analysis using nextgeneration sequencing MicroRNA Gene targeted therapy Immune therapy
下载PDF
Off-label use of targeted therapies in oncology
4
作者 Dominique Levêque 《World Journal of Clinical Oncology》 2016年第2期253-257,共5页
Off-label use is defined by the prescription of a marketed drug outside the conditions described in the summary of product characteristics.In oncology,off-label prescribing of targeted therapies may occur in patients ... Off-label use is defined by the prescription of a marketed drug outside the conditions described in the summary of product characteristics.In oncology,off-label prescribing of targeted therapies may occur in patients with other tumor types expressing the same target.Agents associated to phenotypic approaches such as therapies against the tumoral vasculature(anti-angiogenic drugs) and new immunotherapies(checkpoint inhibitors) also carry the potential of alternative indications or combinations.Off-label use of targeted therapies is little documented and appears to be in the same range than that regarding older drugs with wide variations among agents.When compared with older agents,off-label use of targeted therapies is probably more rational through tumoral genotyping but is faced with a limited clinical support,reimbursement challenges related to the very high pricing and the cost of genotyping or molecular profiling,when applicable. 展开更多
关键词 Targeted therapy Monoclonal antibody Off-label anticancer drug use REIMBURSEMENT Enzyme inhibitor
下载PDF
An Overview of the Connection between Hoarding Disorder and Substance Use Disorder
5
作者 Yibo Wang Tian Tian 《心理学研究评论(中英文版)》 2023年第2期9-11,共3页
This essay explores the connections between Hoarding Disorder and Substance Use Disorder,two distinct mental health conditions with clear diagnostic criteria in the DSM-5.Hoarding Disorder,marked by excessive possessi... This essay explores the connections between Hoarding Disorder and Substance Use Disorder,two distinct mental health conditions with clear diagnostic criteria in the DSM-5.Hoarding Disorder,marked by excessive possession accumulation and difficulties in letting go,affects 2-6%of the global population,leading to severe consequences.Potential causes include genetic predisposition,neural issues,and traumatic experience.Substance Use Disorder is influenced by more societal factors.Both disorders share a comorbidity in Attention-Deficit/Hyperactivity Disorder(ADHD).Network analysis shows a strong direct relationship between Hoarding Disorder and ADHD,while social influences increase ADHD prevalence in Substance Use Disorder individuals.Moreover,both disorders benefit from Cognitive Behavioral Therapy(CBT).Exposure and Ritual Prevention effectively address hoarding symptoms,while CBT for Substance Use Disorder focuses on the interplay between thoughts,emotions,and actions.Despite being classified as a mental illness in DSM-5,Hoarding Disorder receives less attention than Substance Use Disorder.This essay aims to raise awareness of Hoarding Disorder by highlighting its commonalities with Substance Use Disorder in terms of causes,comorbidities,and treatment approaches. 展开更多
关键词 Hoarding Disorder Substance use Disorder ADHD Cognitive Behavioral therapy COMORBIDITY
下载PDF
Prevention of metastasis to liver by using 5-FU intraperitoneal chemotherapy in nude mice inoculated with human colonic cancer cells
6
作者 冯国光 周锡庚 郁宝铭 《World Journal of Gastroenterology》 SCIE CAS CSCD 1996年第3期134-135,共2页
AIMS Using a new approach of regional adjuvant chemotherapy to prevent cancer cells hepatic metasta- sis after radical surgery of large bowel cancer. METHODS A model of liver with metastasis of hu- man colonic cancer ... AIMS Using a new approach of regional adjuvant chemotherapy to prevent cancer cells hepatic metasta- sis after radical surgery of large bowel cancer. METHODS A model of liver with metastasis of hu- man colonic cancer (HCC) cells in nude mice was used to observe the effect in prevention of metastasis of HCC cells inoculated via spleen applied with early postoper- ative intraperitoneal (IP) chemotherapy using large dose of 5-FU. RESULTS The incidence of metastasis to liver was decreased by 40%,the mean number of metastatic liv- er nodules in each animal was reduced by 50.89% and the mean survival times of each animal was prolonged by 48.21% by using 5-FU 40 mg/NS 40 ml/kg IP for two consecutive days as compared with the controls. CONCLUSIONS IP is a new and more effective re- gional adjuvant chemotheraputic approach in the pre- vention of liver metastasis HCC cells after radical surgery of large bowel cancer. 展开更多
关键词 colonic neoplasms/surgery liver neoplasms/drug therapy fluorouracil/thera-peutic use liver neoplasms/secondary
下载PDF
Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected nonresponders and relapsers after interferon alfa-2a monotherapy 被引量:19
7
作者 Perdita Wietzke-Braun Volker Meier +1 位作者 Felix Braun Giuliano Ramadori 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第2期222-227,共6页
AIM To report on the efficacy, safety and tolerability of interferon alfa-2a combined with a "low dose" of ribavirin for relapsers and non responders to alpha interferon monotherapy.METHODS Thirty-four chron... AIM To report on the efficacy, safety and tolerability of interferon alfa-2a combined with a "low dose" of ribavirin for relapsers and non responders to alpha interferon monotherapy.METHODS Thirty-four chronic hepatitis C virus-infected non-responders to interferon alfa2a monotherapy (a course of at least 3 months treatment) and 13 relapsers to interferon alfa 2a monotherapy (a dose of 3 to 6 million units three times per week for at least 20 weeks but not more than 18 months) were treated with the same dose of interferon alfa-2a used before (3 to 6 million units three times per week) and ribavirin (10 mg/ kg daily) for 6 months. In complete responders, interferon alfa-2a was administered for further 6 months at the same dose used before as monotherapy.RESULTS Seven (20.6%) of 34 non-responders stopped the combined therapy due to adverse events, including two patients with histological and clinical Child A cirrhosis. In 17/27 (63%)non-responders, the combined therapy was stopped after three months because of non-response. Ten of the 27 non-responders completed the 1;2-month treatment course. At a mean follow up of 28 months (16- 37 months)after the treatment, 4/10 (15%) previous non-responders still remained complete responders,All 13 previous relapsers completed the 12-month treatment course. At a mean follow up of 22months (9 - 36 months) after treatment, 6/13(46%) the previous relapsers were stillsustained complete responders.CONCLUSION Our treatment schedule of the combined therapy for 6 months of interferon alfa2a with a low dose of ribavirin (10 mg/kg/day)followed by 6 months of interferon alfa-2amonotherapy is able to induce a sustainedcomplete response rate in 15% of non-responders and 46% of relapsers with chronic hepatitis C virus-related liver diseases comparable to those obtained with the standarddoses of ribavirin 1000 - 1200 mg/day.Randomized prospective controlled trials using lower total amounts of ribavirin in combination with interferon should be performed. 展开更多
关键词 hepatitis C chronic/drug therapy INTERFERON alpha-2a/therapeutic use INTERFERON alpha-2a/administration & DOSAGE ribavirin/administration & DOSAGE ribavirin/therapeutic use
下载PDF
Design,delivery and efficacy testing of therapeutic nucleic acids used to inhibit hepatitis C virus gene expression in vitro and in vivo 被引量:9
8
作者 Wolfgang H.Caselmann Matthias Serwe +3 位作者 Thomas Lehmann János Ludwig Brian S.Sproat Joachim W.Engels 《World Journal of Gastroenterology》 SCIE CAS CSCD 2000年第5期626-629,共4页
Despite major achievements in the treatment ofchronic hepatitis C with the combination ofinterferons and the nucleoside analog ribavirin themajority of patients with chronic hepatitis C virus(HCV) infection cannot be ... Despite major achievements in the treatment ofchronic hepatitis C with the combination ofinterferons and the nucleoside analog ribavirin themajority of patients with chronic hepatitis C virus(HCV) infection cannot be treated effectively.Toimprove this response rate we used antisensetechnologies to inhibit HCV translation as possibleadditional option for experimental treatment.Antisense oligodeoxynucleotides(ODN) are 展开更多
关键词 hepatitis C-like viruses/therapy gene expression in VITRO in vivo nucleic acids/therapeutic use CYTOMEGALOVIRUS
下载PDF
Internet addiction and problematic Internet use: A systematic review of clinical research 被引量:16
9
作者 Daria J Kuss Olatz Lopez-Fernandez 《World Journal of Psychiatry》 SCIE 2016年第1期143-176,共34页
AIM: To provide a comprehensive overview of clinical studies on the clinical picture of Internet-use related addictions from a holistic perspective. A literature search was conducted using the database Web of Science.... AIM: To provide a comprehensive overview of clinical studies on the clinical picture of Internet-use related addictions from a holistic perspective. A literature search was conducted using the database Web of Science.METHODS: Over the last 15 years, the number of Internet users has increased by 1000%, and at the same time, research on addictive Internet use has proliferated. Internet addiction has not yet been understood very well, and research on its etiology and natural history is still in its infancy. In 2013, the American Psychiatric Association included Internet Gaming Disorder in the appendix of the updated version of the Diagnostic and Statistical Manual for Mental Disorders(DSM-5) as condition that requires further research prior to official inclusion in the main manual, with important repercussions for research and treatment. To date, reviews have focused on clinical and treatment studies of Internet addiction and Internet Gaming Disorder. This arguably limits the analysis to a specific diagnosis of a potential disorder that has not yet been officially recognised in the Western world, rather than a comprehensive and inclusive investigation of Internet-use related addictions(including problematic Internet use) more generally. RESULTS: The systematic literature review identified a total of 46 relevant studies. The included studies used clinical samples, and focused on characteristics of treatment seekers and online addiction treatment. Four main types of clinical research studies were identified, namely research involving(1) treatment seeker characteristics;(2) psychopharmacotherapy;(3) psychological therapy; and(4) combined treatment. CONCLUSION: A consensus regarding diagnostic criteria and measures is needed to improve reliability across studies and to develop effective and efficient treatment approaches for treatment seekers. 展开更多
关键词 INTERNET ADDICTION PROBLEMATIC INTERNET use Gaming ADDICTION INTERNET Gaming DISORDER Clinical studies TREATMENT seekers TREATMENT therapy
下载PDF
Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children
10
作者 Roberto Caete Angel A Escobedo +1 位作者 María E González Pedro Almirall 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第39期6366-6370,共5页
AIM: To compare the efficacy and safety of five days apostrophe therapy of mebendazole (MBZ) versus quinacrine (QC) on human giardiasis in children.METHODS: A clinical trial was carried out in paediatric patien... AIM: To compare the efficacy and safety of five days apostrophe therapy of mebendazole (MBZ) versus quinacrine (QC) on human giardiasis in children.METHODS: A clinical trial was carried out in paediatric patients (aged 5-15 years) with confirmed symptomatic G. duodenalis mono-infection. Patients were randomly assigned to receive either MBZ [200 mg taken three times per day GRID) (n = 61)] or QC [2 mg/kg bodyweight tid (n = 61)], both for five days. Follow-up faecal samples were obtained at 3, 5 and 7 d after the end of the treatment.RESULTS: Although the frequency of cure was higher for QC (83.6%) than for MBZ (78.7%), the difference was not statistically significant (P 〉 0.05). Adverse events were reported more in the QC group (P 〈 0.05), all of them transient and self-limiting.CONCLUSION: Despite final cure rates ocurring lower than expected, the overall results of this study reconfirmed the efficacy of MBZ in giardiasis and also indicate that, although comparable to QC, at least in this setting the 5 d course of MBZ did not appear to improve the cure rates in this intestinal parasitic infection. 展开更多
关键词 Giardia infection/drug therapy CHILDREN Me- bendazole/therapeutic use Quinacrine/therapeutic use Benzimidazoles/therapeutic use Giardiasis/drug therapy Cuba
下载PDF
High-intensity focused ultrasound extracorporeal ablation of liver tissuesin rabbits
11
《World Journal of Gastroenterology》 SCIE CAS CSCD 1998年第2期16-16,共1页
HighintensityfocusedultrasoundextracorporealablationoflivertissuesinrabbitsCHENGShuQun1,ZHOUXinDa1,TANGZ... HighintensityfocusedultrasoundextracorporealablationoflivertissuesinrabbitsCHENGShuQun1,ZHOUXinDa1,TANGZhaoYou1,YUYao1,B... 展开更多
关键词 LIVER neoplasms experimental/therapy ultrasonic therapy iodized oil/therapeutic use liver/radiation effects randomized controlled trials
下载PDF
Analogous Systems Principles and Concepts of Traditional Chinese Medicine and Congruence Couple Therapy
12
作者 Bonnie K.Lee 《Chinese Medicine and Culture》 2020年第1期22-28,共7页
This article explicates the analogous principles and concepts between traditional Chinese medicine(TCM)and congruence couple therapy(CCT).Although originating out of vastly different times and places,TCM and CCT share... This article explicates the analogous principles and concepts between traditional Chinese medicine(TCM)and congruence couple therapy(CCT).Although originating out of vastly different times and places,TCM and CCT share a view of health based on systems understanding to facilitate the interconnections of the parts of an organism rather than focusing on eliminating symptoms.Both approaches aim to release Qi(气)and vitality by removing blockages through adjusting the interactions,adaptation,and balance of multiple elements and Yin‑Yang energies.The goal is to liberate the Qi or life force through improved holistic balance and cooperation.While TCM focuses on interventions at the level of the body,CCT focuses on the attention,awareness,acknowledgement,and alignment of the four human dimensions consisting of the intrapsychic,interpersonal,intergenerational,and universal‑spiritual.In light of the current trend toward increasing mental,substance use,and neurological disorders,in particular among countries of middle and low income,dialogue to explore these compatibilities between TCM and CCT is conducive to the continuous evolution of TCM and Western therapies to address not only physical health but also the exigencies of contemporary addiction and mental health care within a mind–body relationship matrix. 展开更多
关键词 Addictive disorder congruence couple therapy family therapy mental disorder substance use systemic therapy traditional Chinese medicine Yin‑Yang(阴阳)
下载PDF
吉非替尼对晚期非小细胞肺癌疗效和毒副作用的分析 被引量:14
13
作者 赵明芳 胡雪君 +4 位作者 刘云鹏 于萍 金波 滕月娥 张敬东 《中华肿瘤防治杂志》 CAS 2007年第9期716-718,共3页
收集我科2005年2月~2006年9月病理确诊的复发/转移或局部晚期的非小细胞肺癌(NSCLC)患者36例,单药口服吉非替尼(易瑞沙)250mg/kg,>30d,分析影响吉非替尼疗效和毒副作用的因素。结果:36例患者均可评效,CR1例,PR25例,SD4例,PD6例,客... 收集我科2005年2月~2006年9月病理确诊的复发/转移或局部晚期的非小细胞肺癌(NSCLC)患者36例,单药口服吉非替尼(易瑞沙)250mg/kg,>30d,分析影响吉非替尼疗效和毒副作用的因素。结果:36例患者均可评效,CR1例,PR25例,SD4例,PD6例,客观有效率为72.2%,疾病控制率为83.3%。吸烟与RR、DCR、TTP时间相关(P值分别为0.049、0.024和0.03344),性别、年龄与RR相关(P值分别为0.026和0.028),KPS<60的患者生活质量明显提高,P=0.0482;总的中位TTP为5.5个月。与药物相关的不良反应依次是皮肤干燥、皮疹、腹泻、指(趾)甲改变等不良反应,皮肤干燥和皮疹与RR相关(P值分别为0.012和0.022)。初步研究结果提示,吉非替尼治疗晚期NSCLC的疗效确切,毒副作用小,大多为轻-中度,可耐受。吸烟是预后不良因素,性别、年龄、皮肤干燥和皮疹与近期疗效相关。 展开更多
关键词 非小细胞肺/药物疗法 喹唑啉类 受体 表皮生长因子 回顾性研究
下载PDF
EGFR基因突变与吉非替尼的疗效和获得性耐药关系的研究概况 被引量:9
14
作者 于国华 董丽萍 刘淑真 《中华肿瘤防治杂志》 CAS 2007年第6期474-476,共3页
肿瘤的分子靶向治疗是近年发展起来的一种全新的治疗手段。吉非替尼(Gefitinib)是晚期非小细胞肺癌(NSCLC)治疗中的第1个靶向药物,具有特异性强,起效快,不良反应少的特点。其作用机制是抑制表皮生长因子受体(EGFR)酪氨酸激酶的活性,阻断... 肿瘤的分子靶向治疗是近年发展起来的一种全新的治疗手段。吉非替尼(Gefitinib)是晚期非小细胞肺癌(NSCLC)治疗中的第1个靶向药物,具有特异性强,起效快,不良反应少的特点。其作用机制是抑制表皮生长因子受体(EGFR)酪氨酸激酶的活性,阻断EGFR生成信号传递至细胞内,从而抑制肿瘤细胞的异常增生和转移。临床疗效与EGFR基因的突变具有一定的相关性。EGFR基因突变有外显子19碱基缺失,外显子20的点突变或碱基插入突变和外显子21的点突变3种类型。其中外显子20的点突变可能是肿瘤细胞对Gefitinib产生抗药性的原因。EGFR基因的突变在东方人群,女性,腺癌和非吸烟人群中高表达,而且临床应用中已经证实Gefitinib在上述人群中有效率最高。EGFR基因在应用Gefitinib的过程中亦会发生二次突变,这可能是Gefitinib获得性耐药的机制,但亦有研究显示Gefitinib的耐药与药物的转运、EGFR基因的扩增以及信号通路的改变有关,非单一机制能完全解释其耐药性。所以如何利用EGFR来准确预测Gefitinib的有效性,预防和阻止Gefitinib耐药将是今后对EGFR和Gefitinib研究的重点。 展开更多
关键词 表皮生长因子受体 喹唑啉类/治疗应用 耐药 综述文献
下载PDF
吉非替尼治疗晚期肺腺癌的临床观察 被引量:13
15
作者 程刚 伍建宇 张永强 《中华肿瘤防治杂志》 CAS 2008年第4期289-292,共4页
目的:探讨吉非替尼(易瑞沙)治疗晚期肺腺癌的疗效及生存期。方法:对45例ⅢB~Ⅳ期经化疗失败的或不能耐受化疗及不愿接受化疗的晚期肺腺癌用吉非替尼每次250mg/d口服。第1次用药后4周评价疗效,以后每8周1次或出现新的症状及原有症状加... 目的:探讨吉非替尼(易瑞沙)治疗晚期肺腺癌的疗效及生存期。方法:对45例ⅢB~Ⅳ期经化疗失败的或不能耐受化疗及不愿接受化疗的晚期肺腺癌用吉非替尼每次250mg/d口服。第1次用药后4周评价疗效,以后每8周1次或出现新的症状及原有症状加重时随时评价。结果:本组可评价疗效40例,完全缓解(CR)2例,部分缓解(PR)14例,客观缓解率(CR+PR)为40%;疾病控制率(CR+PR+SD)为77.5%,中位疾病进展时间(TTP)为5.43个月,中位生存期为12.20个月;1、2年生存率分别为48.15%和24.07%。亚组分析显示,ECOGPS评分≥2分的生存期(3.97个月)明显差于PS<2分的(19.87个月),P=0.0000;而从吸烟状况、性别、有无化疗及年龄上来看,不吸烟、女性明显好于吸烟、男性,但差异无统计学意义;而有无化疗及年龄≥70或<70岁差异均无统计学意义。最常见的毒副反应为皮疹[68.8%(31/45)]和腹泻[33.3%(15/45)],多为轻度;有2例可疑间质性肺病变。结论:吉非替尼对晚期肺腺癌的疗效可靠,安全性好。ECOGPS评分对其疗效有明显的影响;是否吸烟及性别状况对其疗效有影响的趋势,而之前有无化疗及年龄的因素对其影响不大。 展开更多
关键词 肺肿瘤/药物疗法 非小细胞肺 腺癌 受体 表皮生长因子 喹唑啉类
下载PDF
吉非替尼治疗非小细胞肺癌优势人群与非优势人群的比较研究 被引量:6
16
作者 钱军 秦叔逵 +3 位作者 杨柳青 陈映霞 何泽明 黄勇 《中华肿瘤防治杂志》 CAS 2006年第24期1882-1884,共3页
目的:观察吉非替尼治疗非小细胞肺癌(NSCLC)中优势人群的情况,以同期、同样治疗的NSCLC非优势人群作为对照,比较两组治疗的有效性和安全性。方法:全组共有NSCLC患者73例,均经病理组织学或细胞学检查确诊,其中33例完全符合优势人群的标准... 目的:观察吉非替尼治疗非小细胞肺癌(NSCLC)中优势人群的情况,以同期、同样治疗的NSCLC非优势人群作为对照,比较两组治疗的有效性和安全性。方法:全组共有NSCLC患者73例,均经病理组织学或细胞学检查确诊,其中33例完全符合优势人群的标准,即东方人种、女性、腺癌和非吸烟者;另外40例不符合者作为非优势人群,既往化疗效果差,均自愿接受吉非替尼单药250 mg/d治疗。结果:33例优势人群接受吉非替尼治疗后PR 15例,SD 14例,PD 4例,有效率为45.4%(15/33),DCR 87.8%(29/33),中位疾病进展时间(TTP)7个月,治疗后中位生存期9个月;而40例非优势人群治疗后PR 9例,SD 21例,PD 10例,有效率22.5%(9/40),DCR 75.0%(30/40),中位TTP 5个月,治疗后中位生存期7个月。全组患者中,腺癌和非腺癌的有效率分别为38.3%(23/60)和7.7%(1/13)。两组毒副反应一致。结论:对于NSCLC国人患者,认真挑选优势人群,合理而有计划地应用分子靶向治疗药物吉非替尼,疗效较高,可能有助于提高临床个体化治疗水平。 展开更多
关键词 非小细胞肺/药物疗法 抗肿瘤药/治疗应用 喹唑啉类/治疗应用
下载PDF
厄洛替尼治疗NSCLC致急性间质性肺疾病的临床分析 被引量:2
17
作者 王娜娜 谭效锋 +3 位作者 沈虹 吕元军 杨书香 潘文胜 《实用肿瘤杂志》 CAS 2013年第6期623-627,共5页
报道1例厄洛替尼治疗非小细胞肺癌导致急性间质性肺疾病(interstitial lung disease,ILD),并通过文献检索收集到24例病例报道。在这24例病例中,急性间质性肺疾病发生于服用厄洛替尼后的5天-1年,75.0%(18/24)的病例在服药后5-39天出现ILD... 报道1例厄洛替尼治疗非小细胞肺癌导致急性间质性肺疾病(interstitial lung disease,ILD),并通过文献检索收集到24例病例报道。在这24例病例中,急性间质性肺疾病发生于服用厄洛替尼后的5天-1年,75.0%(18/24)的病例在服药后5-39天出现ILD。ILD的危险因素包括高龄、男性、吸烟史、基础肺疾病史、放化疗史。11例死于呼吸衰竭,合并高危因素的患者死亡率更是高达50%。 展开更多
关键词 非小细胞肺 药物疗法 肺疾病 间质性 并发症 蛋白酪氨酸激酶类 拮抗剂和抑制剂 受体 表皮生长因子 喹唑啉类 副作用 喹唑啉类 治疗应用 回顾性研究
下载PDF
吉非替尼治疗晚期肺腺癌多脏器转移的临床观察 被引量:2
18
作者 张凤 邢丽娜 马艳伟 《中华肿瘤防治杂志》 CAS 2007年第17期1341-1342,共2页
为了探讨吉非替尼(易瑞沙)单药治疗进展的晚期肺腺癌多脏器转移患者的疗效与不良反应,18例合并多脏器转移的进展的晚期肺腺癌患者接受治疗。易瑞沙250mg口服,每日1次,服用至疾病进展或出现不可耐受的不良反应。治疗后每4周复查1次,16周... 为了探讨吉非替尼(易瑞沙)单药治疗进展的晚期肺腺癌多脏器转移患者的疗效与不良反应,18例合并多脏器转移的进展的晚期肺腺癌患者接受治疗。易瑞沙250mg口服,每日1次,服用至疾病进展或出现不可耐受的不良反应。治疗后每4周复查1次,16周后每8周复查1次。结果:本组18例患者均可评价疗效。其中完全缓解1例,部分缓解6例,无变化4例,进展7例。有效率为38.8%,疾病控制率61.1%。临床获益率为44.4%,常见不良反应为Ⅰ、Ⅱ度皮肤改变和腹泻,未发生Ⅲ度以上不良反应。初步研究结果提示,易瑞沙治疗化疗后进展的晚期肺腺癌合并多脏器转移的疗效显著,不良反应轻,是晚期肺腺癌多脏器转移患者的最佳选择之一。 展开更多
关键词 肺肿瘤 药物疗法 受体 表皮生长因子 喹唑啉类
下载PDF
吉非替尼治疗女性晚期复治NSCLC的临床研究 被引量:1
19
作者 吴东平 徐农 +3 位作者 方维佳 张晓琛 陈敬 钱炯 《实用肿瘤杂志》 CAS 北大核心 2011年第2期187-190,共4页
目的评价吉非替尼治疗女性晚期复治非小细胞肺癌的疗效和安全性。方法 32例患者接受口服吉非替尼250 mg/d治疗,直至病情进展或不能耐受。中位给药时间11.8月(2-52月)。结果随访至2010年1月1日,中位随访期20.2月,死亡19例,进展4例。32例... 目的评价吉非替尼治疗女性晚期复治非小细胞肺癌的疗效和安全性。方法 32例患者接受口服吉非替尼250 mg/d治疗,直至病情进展或不能耐受。中位给药时间11.8月(2-52月)。结果随访至2010年1月1日,中位随访期20.2月,死亡19例,进展4例。32例患者CR 1例(3.1%),PR 19例(59.4%),SD 11例(34.4%),PD 1例(3.1%)。客观有效率为62.5%,疾病控制率为96.9%;无进展生存期(PFS)13.0月,1年无进展生存率50.9%,2年无进展生存率33.4%;中位生存期24.0月,1年生存率80.3%,2年生存率46.2%,3年生存率27.7%。与药物相关的毒副反应依次为皮疹27例(84.4%),腹泻15例(46.9%),食欲缺乏6例(18.8%),乏力5例(15.6%)。结论吉非替尼治疗女性晚期复治非小细胞肺癌有效,不良反应低。性别是晚期肺癌选择药物治疗及判断预后、疗效的一个重要临床因素,对于晚期、复治的女性非小细胞肺癌,可选择吉非替尼治疗。 展开更多
关键词 非小细胞肺/药物疗法 喹唑啉类/治疗应用 生存率
下载PDF
吉非替尼与厄罗替尼治疗晚期非小细胞肺癌的临床分析 被引量:5
20
作者 王治华 唐勇 +2 位作者 曲彦丽 单利 赛福丁 《实用肿瘤杂志》 CAS 北大核心 2010年第2期195-199,共5页
目的观察靶向药物吉非替尼与厄罗替尼治疗中晚期(ⅢB/Ⅳ期)非小细胞肺癌(NSCLC)的疗效及不良反应。方法将58例中晚期非小细胞肺癌患者分成吉非替尼方案组(A组,33例)和厄罗替尼方案组(B组,25例),分别口服吉非替尼(250mg)和厄罗替尼(150mg... 目的观察靶向药物吉非替尼与厄罗替尼治疗中晚期(ⅢB/Ⅳ期)非小细胞肺癌(NSCLC)的疗效及不良反应。方法将58例中晚期非小细胞肺癌患者分成吉非替尼方案组(A组,33例)和厄罗替尼方案组(B组,25例),分别口服吉非替尼(250mg)和厄罗替尼(150mg),1次/日。结果A组有效率27.3%,疾病控制率为45.5%,B组有效率44.0%,疾病控制率为60.0%,两者差异无统计学意义(P>0.05);无疾病进展时间:A组4.5月,B组5.0月;中位生存期:A组9.0月,B组8.0月,以上差异均无统计学意义(P>0.05);两者毒副反应为皮疹与腹泻,其中A组为57.3%、18.2%,B组为64.0%、12.0%,两者无明显统计学差异(P>0.05)。结论吉非替尼与厄罗替尼治疗中晚期非小细胞肺癌的有效率差别不大,对于晚期非小细胞肺癌均有较好的疗效与安全性。 展开更多
关键词 非小细胞肺/药物疗法 喹唑啉类/治疗应用 肺肿瘤/药物疗法
下载PDF
上一页 1 2 3 下一页 到第
使用帮助 返回顶部